Hanmi’s Poziotinib proved innovative efficacy for NSCLC patients

Published: 2017-10-20 15:50:23

Updated: 2017-10-20 15:50:23

The advanced clinical result of ‘Poziotinib,’ a novel anticancer drug developed by Hanmi Pharm and licensed to Spectrum Pharmaceuticals, was revealed on the 18^th at the World Conference on Lung Cancer(WCLC) in Yokohama, Japan.

Dr. John Heymach from the University of Texas MD Anderson Cancer Center, a world’s well-known expert in the clinical oncology field, announced “Poziotinib showed innovat...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.